1. Fulfilling an unmet need in psoriasis: do biologicals hold the key to improved tolerability?;Shear;Drug Saf,2006
2. Psoriatic disease and tuberculosis nowadays;Balato;Clin Dev Immunol,2012
3. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept;Lee;Arthritis Rheum,2002
4. FDA. U.S. Food and Drug Administration Postmarket Drug Safety Information for Patients and Providers - Information for Healthcare Professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab) 2010 http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124185.htm
5. High prevalence of latent tuberculosis infection in autoimmune disorders such as psoriasis and in chronic respiratory diseases, including lung cancer;Bordignon;J Biol Regul Homeost Agents,2011